Alyeska Investment Group
ESPR

Alyeska Investment Group’s Esperion Therapeutics ESPR Stock Holding History

Alyeska Investment Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-142,857
Closed -$714K – 600
2021
Q4 		$714K Buy
+142,857
New +$1.14M 0.01% 549
2014
Q1 		– Sell
-73,970
Closed -$1.02M – 343
2013
Q4 		$1.02M Sell
73,970
-67,016
-48% -$975K 0.04% 266
2013
Q3 		$2.66M Sell
140,986
-3,514
-2% -$59K 0.11% 200
2013
Q2 		$2.04M Buy
+144,500
New +$2.05M 0.1% 197

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Alyeska Investment Group's ESPR Position: Q1 2022 in Review

Alyeska Investment Group sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 142,857 shares — an estimated $714K sold.

Alyeska Investment Group first reported a position in ESPR in Q2 2013 and held it in 4 quarters. The position peaked at $2.66M in Q3 2013. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Alyeska Investment Group reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 142,857 Esperion Therapeutics shares in Q1 2022, an estimated $714K.
  • Alyeska Investment Group first reported a position in Esperion Therapeutics in Q2 2013 and held it in 4 quarters.
  • Alyeska Investment Group's Esperion Therapeutics position peaked at $2.66M in Q3 2013.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Alyeska Investment Group's 13F filing for Q1 2022, filed 16 May 2022.